Tirzepatide 15mg (GLP-2 T)
Dual GIP/GLP-1 agonist — the most effective weight loss peptide in clinical trials.
14.9%
Avg body weight reduction
68wk
STEP-1 trial duration
FDA
Reviewed mechanism
Tirzepatide is a dual GIP/GLP-1 receptor agonist that achieved 20.9% average weight loss in Phase 3 trials — the greatest weight reduction of any peptide in clinical history.
20.9% Weight Loss
SURMOUNT-1 data — the largest weight reduction ever documented in a Phase 3 anti-obesity trial.
Dual Agonist
GIP + GLP-1 dual activation produces greater weight loss than either target alone — synergistic mechanism.
56% Lose 20%+
At 15mg, 56% of subjects lost more than 20% of body weight — results previously achievable only through surgery.
Tirzepatide (GLP-2 T) 15mg: The Complete Dual Agonist Protocol
Mechanism · Evidence · Application
Tirzepatide is the most effective anti-obesity peptide ever studied in Phase 3 clinical trials. As a dual GIP (Glucose-Dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptor agonist, tirzepatide activates two complementary metabolic regulatory pathways simultaneously.
The GIP + GLP-1 Dual Mechanism
GIP and GLP-1 are the two primary incretins — gut hormones released in response to eating. While GLP-1 (targeted by semaglutide) has been well-characterized, GIP's role in weight regulation was less understood until tirzepatide's development.
Tirzepatide's dual mechanism produces effects exceeding either agonist alone: - GIP activation: Enhances insulin sensitivity, promotes adipose lipolysis, and modulates food reward pathways - GLP-1 activation: Reduces appetite, slows gastric emptying, and regulates glucose metabolism - Combined: The dual signal appears to produce synergistic — not merely additive — effects on body weight
SURMOUNT Trial Data
The SURMOUNT-1 Phase 3 trial is the landmark dataset: - 20.9% average body weight reduction at 72 weeks (5mg–15mg dose range) - 56% of participants lost 20%+ of body weight at the highest dose - 82% of participants at 15mg achieved at least 5% weight loss - Improvements in blood pressure, lipids, insulin resistance, and liver fat
Metabolic & Weight Loss Results
20.9% average weight loss in SURMOUNT-1 — the most ever documented for a single peptide
56% of subjects lost 20%+ of body weight at 15mg — surgical-level weight loss
Dual GIP + GLP-1 activation — superior to single-agonist protocols
Significantly improves insulin resistance and type 2 diabetes markers
Reduces visceral and liver fat more than semaglutide in head-to-head data
Once-weekly subcutaneous injection due to ~5-day half-life
Improves cardiovascular risk markers: blood pressure, LDL, triglycerides
Preserves lean muscle mass at higher rates than earlier GLP-1 agents
Weight Loss Protocol Guide
Tirzepatide 15mg (GLP-2 T) Protocol Guide
Escalation Protocol (16 weeks to maintenance):
· Weeks 1–4: 2.5mg once weekly
· Weeks 5–8: 5mg once weekly
· Weeks 9–12: 7.5mg once weekly
· Weeks 13–16: 10mg once weekly
· Weeks 17+: 12.5–15mg once weekly (maximum)
Injection Instructions:
· Once-weekly subcutaneous injection (abdomen, thigh, or upper arm)
· Rotate injection sites each week
· May take with or without food
· Same day of week for consistent plasma levels
Tirzepatide 15mg (GLP-2 T)
Apollo Peptides Sciences
$149.99
Buy from ApolloAffiliate link · supports PeptidesClav
Body Composition
Dual GIP/GLP-1 agonist — the most effective weight loss peptide in clinical trials.
Quality Assurance
HPLC Testing
Purity verified per batch
Mass Spectrometry
Molecular identity confirmed
Certificate of Analysis
Publicly available
US-Based Supplier
Apollo Peptides Sciences
Synergistic Combinations
Stack Tirzepatide 15mg (GLP-2 T) With
Ready to Start?
Begin your Tirzepatide 15mg (GLP-2 T) protocol
Source from Apollo Peptides Sciences — HPLC-tested, mass-spectrometry verified, with a Certificate of Analysis per batch.
Shop Tirzepatide 15mg (GLP-2 T) at Apollo